- 25 April
-
From April 15 to 18, Ekaterinburg hosted the 6th international specialized exhibition and forum Healthcare of the Urals–2025. This year, 130 companies from 34 cities of Russia and the Republic of Belarus took part in the event, presenting over 1000 units of medical equipment and goods. The residents of the Ural Biomedical Cluster were traditionally among the participants, as well as its collective member – the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region.
- 10 April
-
On April 6, the First Children's Polyclinic in the Akademichesky District celebrated its 10th anniversary. During this time, the institution has become a flagship of high-quality and affordable medical care for children, serving 33,083 young patients. The polyclinic was created by the initiative of the Ural Biomedical Cluster and the Governor of the Sverdlovsk Region and became a successful example of public-private partnership.
- 27 March
-
A meeting of the Committee on Entrepreneurship in Healthcare and Medical Industry of the Ural Chamber of Commerce and Industry was held in Ekaterinburg on March 18, 2025, chaired by Alexander Petrov. Participants of the event, including representatives of the Association of Medical Specialists for Risk Modification, the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, the Ural Biomedical Cluster and members of the Committee considered key challenges in maintaining the health of the able-bodied population, fighting against socially significant diseases and regulating prices for vital drugs.
- 05 December
-
The Russian pharmaceutical industry has gained significant stability in the recent years thanks to manufacturers such as Medsintez Plant. This is a modern full-cycle biotechnological enterprise that develops and manufactures pharmaceutical ingredients and drugs that meet international GMP and ISO standards.
- Home
- Cluster members
- Ural Biomedical Company LLC
Ural Biomedical Company LLC
Genetic and gene and cell technologies (GCT), which make it possible to modify the properties of cells in a targeted manner, is a direction that the UN has officially recognized as a technology of the 21st century.
Hopes for the treatment of the most severe and massive diseases, such as cardiovascular, oncological and metabolic diseases, are associated with success in the development of GCT.
The small innovative enterprise Ural Biomedical Company LLC acts as a coordinator in this area, bringing together the efforts of specialists from the Department of Molecular and Cellular Technologies of the Ural State Medical University and the Laboratory of Cell and Gene Therapy Technology of the Institute of Medical Cellular Technologies in conducting an R&D cycle and implementing innovative projects for the development, production and use of a new generation of personalized medicines based on gene and gene-cell technologies based on the patented developments of one of the leading scientific schools in Russia – Professor O. G. Makeev's School.
Currently, the studies coordinated by Ural Biomedical Company LLC are at different stages of preclinical and clinical trials, which are highly recognized both in Russia and abroad – in particular, representatives of the above scientific school have obtained dozens of patents, have been awarded gold medals at European and Russian forums and exhibitions of biomedical technologies.
According to the National Society of Regenerative Medicine, a unique product for the Russian and world markets – AversGel – a gel for natural skin rejuvenation based on components of a certified human stem cell line, entered the top 10 breakthrough technologies in Russia in 2017 with the comment: "These technologies will remain with us for a long time. They will change the economy and politics, make a breakthrough in medicine, leave a cultural mark. Some of them are just taking shape, while others can take more than a decade to develop. But you need to know about them right now.”
